Grant: Team Grant: DM/TS - CIHR-JDRF - ß-cell and Pancreatic Islet Physiology - LOI
University of Alberta
$10,000.00
A First-in-human Trial of Autologous Induced Pluripotent Stem Cell (iPSC)-Derived Islets: Developing a Personalized Diabetes Therapy
FY 2020-21
Summary
Diabetes is caused by the lack of insulin, a hormone produced by the islet ß-cells in the pancreas that regulates blood sugar. In Type 1 Diabetes (T1D, ~10%), the ß-cells are destroyed by one's own immune system. In Type 2 Diabetes (T2D, ~90%), the body becomes more resistant to insulin, increasing the demand and eventually leading to ß-cell damage. Chronically high blood sugar can cause complications such as blindness, amputations, stroke, heart disease, kidney failure and shortened lifespan. Insulin injection is life-saving but remains not a cure. Islet transplant has been successful in treating some patients with T1D; however, it requires life-long anti-rejection (immunosuppression) drugs and is limited by the scarcity of organ donors.
Building on our 20 years of experience in islet transplant, our team will take advantage of our expertise in stem cell and islet biology, immunology, and transplantation to address these challenges by developing a stem-cell based therapy to replace or supplement damaged ß-cells in people with all types of diabetes, including T1D, T2D, and surgical diabetes after total pancreatectomy. We propose to manufacture new ß-like cells from their own blood cells, so that they will be accepted by the immune system and no/minimal anti-rejection drugs are needed. In this project, we will conduct a First-in-human trial to implant these cells under the patient's skin and evaluate their safety and preliminary efficacy. Manufacturing protocols will be optimized to allow development and scale-up of clinical grade products for therapy. Being able to transplant an unlimited supply of self-derived islet cells without immunosuppressants is a novel approach to treat all forms of diabetes and could be the world's first functional cure.
Department
Program
Team Grant: DM/TS - CIHR-JDRF - ß-cell and Pancreatic Islet Physiology - LOI
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
446711
Name
Shapiro James
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Team Grant: Diabetes Mechanisms and Translational Solutions - LOI
Projecttitle
A First-in-human Trial of Autologous Induced Pluripotent Stem Cell (iPSC)-Derived Islets: Developing a Personalized Diabetes Therapy
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$10,000
Cihrequipment2
$0
Programname2
Team Grant: DM/TS - CIHR-JDRF - ß-cell and Pancreatic Islet Physiology - LOI
Keyworddelim
Beta Cell Replacement Therapy; Induced Pluripotent Stem Cells; Treatment For Diabetes
Abstract
Diabetes is caused by the lack of insulin, a hormone produced by the islet ß-cells in the pancreas that regulates blood sugar. In Type 1 Diabetes (T1D, ~10%), the ß-cells are destroyed by one's own immune system. In Type 2 Diabetes (T2D, ~90%), the body becomes more resistant to insulin, increasing the demand and eventually leading to ß-cell damage. Chronically high blood sugar can cause complications such as blindness, amputations, stroke, heart disease, kidney failure and shortened lifespan. Insulin injection is life-saving but remains not a cure. Islet transplant has been successful in treating some patients with T1D; however, it requires life-long anti-rejection (immunosuppression) drugs and is limited by the scarcity of organ donors.
Building on our 20 years of experience in islet transplant, our team will take advantage of our expertise in stem cell and islet biology, immunology, and transplantation to address these challenges by developing a stem-cell based therapy to replace or supplement damaged ß-cells in people with all types of diabetes, including T1D, T2D, and surgical diabetes after total pancreatectomy. We propose to manufacture new ß-like cells from their own blood cells, so that they will be accepted by the immune system and no/minimal anti-rejection drugs are needed. In this project, we will conduct a First-in-human trial to implant these cells under the patient's skin and evaluate their safety and preliminary efficacy. Manufacturing protocols will be optimized to allow development and scale-up of clinical grade products for therapy. Being able to transplant an unlimited supply of self-derived islet cells without immunosuppressants is a novel approach to treat all forms of diabetes and could be the world's first functional cure.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shapiro, James; Kieffer, Timothy J; Korbutt, Gregory S; MacDonald, Patrick E; Pepper, Andrew R
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $10,000~ $0~